Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies

Off-target toxicity due to the expression of target antigens in normal tissue represents a major obstacle to the use of chimeric antigen receptor (CAR)-engineered T cells for treatment of solid malignancies. To circumvent this issue, we established a clinical platform for engineering T cells with tr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Beatty, Gregory L., Haas, Andrew R., Maus, Marcela V., Torigian, Drew A., Soulen, Michael C., Plesa, Gabriela, Chew, Anne, Zhao, Yangbing, Levine, Bruce L., Albelda, Steven M., Kalos, Michael, June, Carl H.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3932715/
https://ncbi.nlm.nih.gov/pubmed/24579088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-13-0170
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars